Articles

Dapiglutide GLP-1/GLP-2 Trial: 2026 Obesity Treatment Update — an overview of this emerging metabolic peptide candidate ...

Efsubaglutide Alfa: What the Super-1 GLP-1 Trial Shows — an overview of this emerging metabolic peptide candidate and wh...

A patient-safety coalition wants the FDA to block compounding of seven peptides and to set aside the July advisory vote ...

Vanda's oral NK-1 blocker cut GLP-1 vomiting 27% in a Phase 3 trial, with an 81% drop in extreme cases. A supplemental F...

Amycretin vs Cagrisema: Comparing Two Metabolic Peptide Combos — an overview of this emerging metabolic peptide candidat...

CT-388: Dual Agonist Dosing and Early Trial Data — an overview of this emerging metabolic peptide candidate and what the...

A New Jersey federal judge refused to block Eli Lilly's weight-loss ads, finding Novo Nordisk failed to show irreparable...

Lilly has registered AMPLIFY-1 and AMPLIFY-2, two Phase 3 trials of its amylin-tirzepatide combination enrolling 3,115 p...

Corxel Pharmaceuticals will merge with Amanat Acquisition Corp, raising about $377 million to fund Phase 3 testing of it...

Amycretin Explained: The Next Generation GLP-1 Candidate — an overview of this emerging metabolic peptide candidate and ...

Amycretin Dosing Guide: What Early Research Suggests — an overview of this emerging metabolic peptide candidate and what...

Real-world records from nearly 48 million US adults show oral semaglutide initiation peaked 10 weeks after approval, bri...

A Texas federal judge denied Strive Specialties' bid to revive its antitrust suit against Eli Lilly and Novo Nordisk ove...

Research suggests GLP-1 therapy may have protective effects against age-related macular degeneration — an unexpected pot...

Using GLP-1 therapy before bariatric surgery can improve surgical outcomes — here's the emerging protocol....

Surging GLP-1 demand and telehealth prescribing have made provider follow-up the decisive safety factor in weight care, ...

Orforglipron met cardiovascular safety goals in ACHIEVE-4: MACE 4.2% vs 5.0% on insulin glargine, with A1C and weight be...

Can GLP-1 therapy support body recomposition — simultaneous fat loss and muscle gain? The evidence is encouraging....

Understanding and tracking appetite changes on GLP-1 therapy helps optimize dosing and long-term adherence....

Large randomized trials are testing whether GLP-1 medications like semaglutide can reduce alcohol and opioid cravings, e...

GLP-1 therapy slows gastric emptying, creating important considerations for perioperative care and anesthesia....

Real-world evidence from millions of GLP-1 users provides the most comprehensive safety picture to date....

GLP-1 users spend 26% more on fragrances, NIQ data shows, as dampened food reward shifts sensory pleasure toward scent a...

A systematic review of GLP-1 therapy in non-diabetic populations confirms significant weight loss with manageable safety...

A comprehensive nutrition strategy for GLP-1 therapy users — focusing on protein intake, meal timing, and metabolic supp...

Novo Nordisk's post hoc REDEFINE 1 analysis reports 25% average weight loss in women on CagriSema at 68 weeks, consisten...

Apothecary Pharma recalled 22 compounded tirzepatide vials nationwide after sterility could not be assured. FDA classed ...

What works for preserving muscle on GLP-1 therapy? This meta-analysis reviews the evidence for various intervention stra...

Practical, evidence-based strategies for maintaining muscle mass while benefiting from GLP-1 weight loss therapy....

The FDA is warning buyers about copycat GLP-1 drugs after a nationwide compounded tirzepatide recall. Here is how to che...

Which peptide treatments hold real FDA approval? PepsReview maps approved GLP-1 drugs against unapproved gray-market pep...

A new consumer analysis of Wegovy vs. Ozempic highlights semaglutide brand confusion — and why that confusion feeds the ...

A new signal in GLP-1 therapy data raises questions about breast cancer risk — here's what researchers are investigating...

A comprehensive meta-analysis quantifies the lean mass loss associated with GLP-1 therapy and what it means for long-ter...

GLP-1 receptor agonists can improve sleep for some users while disrupting it for others — here's what the research shows...

Emerging research on GLP-1 therapy and biological aging markers suggests potential anti-aging effects beyond weight loss...

One in six children on GLP-1s developed a nutritional deficiency within a year, claims study finds, with vitamin D short...

Twenty state attorneys general tell the State Department the FDA Green List lets Chinese suppliers ship unapproved GLP-1...

Real-world OCTANE study: patients switching from GLP-1 injections to the semaglutide pill kept losing weight, 4.1% over ...

Analysis of 636,525 records: escalating semaglutide to 2 mg tied to 6% lower cardiovascular risk than switching to tirze...

NIH-funded UC Berkeley research shows semaglutide extended lifespan in older mice and improved muscle, memory, and blood...

Cagrilintide Dosage Guide: Amylin Analog Protocol — an overview of this emerging metabolic peptide candidate and what th...

Cagrisema: The Amylin-GLP-1 Combination Explained — an overview of this emerging metabolic peptide candidate and what th...

FDA and HHS scrutiny of the peptide wellness market is tightening. PepsReview Editorial explains what regulatory analysi...

Kisspeptin-10: The Reproductive Health Peptide Guide — a detailed guide covering mechanism, dosing, and research evidenc...

SLU-PP-332: Exercise Mimetic Peptide Complete Guide — an overview of this emerging metabolic peptide candidate and what ...

Peptide therapy runs $500 to $1,500 a month cash-pay while FDA decides if compounding BPC-157 and TB-500 stays legal — w...

CHMP has recommended Eli Lilly's Foundayo (orforglipron) for EU approval — the first non-peptide GLP-1 pill, cleared for...

Novo Nordisk South Africa has reported 39 suspected unlawful medicine cases in 2026, most tied to Instagram and WhatsApp...

South African drugmakers are urging police to prosecute illicit obesity-drug sellers, naming unapproved retatrutide sold...

South Africa's pharmacy council and medicines regulator are rewriting compounding rules, with revised standards due for ...

NAD+ Peptide Stacking: Combining with Other Longevity Peptides — a detailed guide covering mechanism, dosing, and resear...

Cycling NAD+: Should You Take Breaks from Supplementation? — a detailed guide covering mechanism, dosing, and research e...

Lab testing in Ireland found significant impurities in 3 of 4 gray-market peptide products, with one Melanotan vial only...

FDA inspection records reveal black mold, hidden paperwork, and fabricated documents at two Chinese plants supplying GLP...

Dihexa Nootropic Peptide: What the Research Actually Shows — a detailed guide covering mechanism, dosing, and research e...

NAD+ 1000mg Reconstitution Guide: Diluent Math and Protocols — a detailed guide covering mechanism, dosing, and research...

Hepatology specialists publish the first selection algorithm for resmetirom and semaglutide, the two FDA-approved MASH t...

FDA warning letters hit two online sellers of unapproved semaglutide branded as Indian-made products, with no valid U.S....

Poison centers logged 862 bootleg retatrutide exposures from July to September 2026, nearly double the prior quarter, as...

Cerebrolysin as a Nootropic: Peptide Guide for Cognitive Enhancement — a detailed guide covering mechanism, dosing, and ...

Cerebrolysin Administration: Subcutaneous vs Intravenous Comparison — a detailed guide covering mechanism, dosing, and r...

Verdiva Bio terminated its Phase 2 weight-maintenance trial of oral GLP-1 VRB-101, citing a business decision. The monot...

Amylin weight-loss candidates from Novo Nordisk, Eli Lilly, and Zealand Pharma enter late-stage trials, with an FDA deci...

Two deaths reported to the FDA have put bootleg Reta retatrutide under scrutiny. Here is what the reports do and do not ...

Semax Nootropic Peptide: Cognitive Enhancement Guide — a detailed guide covering mechanism, dosing, and research evidenc...

Survodutide Dosing Guide: GLP-1/Glucagon Protocol — an overview of this emerging metabolic peptide candidate and what th...

Oral semaglutide passed 100,000 US prescriptions in two months — the fastest weight-loss drug launch on record, an Annal...

Eli Lilly files a second wave of lawsuits against five more companies selling unapproved retatrutide, pressing regulator...

Randomized-trial data show semaglutide slowed epigenetic aging clocks up to 9% in HIV lipodystrophy patients, with tirze...

Selank 10mg Reconstitution: Step-by-Step Guide — a detailed guide covering mechanism, dosing, and research evidence for ...

Selank and Semax Stack: Nootropic Peptide Protocol Guide — a detailed guide covering mechanism, dosing, and research evi...

Months after the FDA called its Wegovy pill ad misleading, Novo Nordisk now markets to customers, not patients - and the...

The FDA flagged GLP-1 vision-loss signals in 2025, yet U.S. Ozempic and Mounjaro labels still carry no NAION warning whi...

FDA's proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list awaits a final decision. Wha...

Epitalon for Anti-Aging: Telomere Peptide Science Explained — a detailed guide covering mechanism, dosing, and research ...

Epithalon Longevity Guide: How This Peptide Supports Healthy Aging — a detailed guide covering mechanism, dosing, and re...

Lilly's FDA-approved Foundayo (orforglipron) is the first non-peptide GLP-1 weight-loss pill, with 12.4% trial weight lo...

Novo Nordisk's first-in-class amycretin (zenagamtide) produced up to 14.6% weight loss and 1.71-point HbA1c cuts in a ph...

Thousands of GLP-1 injury lawsuits advance while regulators admit data on serious harms stay thin. Here is what the evid...

AOD-9604 Fat Loss Protocol: What the Research Shows — a detailed guide covering mechanism, dosing, and research evidence...

PT-141 (Bremelanotide): Libido Enhancement Peptide Guide — a detailed guide covering mechanism, dosing, and research evi...

FDA warning letters target online peptide sellers, but overseas supply chains, mislabeled imports and $32M in quarterly ...

Sermorelin for Natural Growth Hormone Optimization: Complete Guide — a detailed guide covering mechanism, dosing, and re...

Melanotan 2: Tanning Peptide Guide and Safety Considerations — a detailed guide covering mechanism, dosing, and research...

Americans buying cheap online semaglutide may be paying the same Chinese chemical vendors that also sell fentanyl precur...

South Korea's drug regulator has approved Hanmi's EPPE, the first domestically developed GLP-1 obesity drug, based on Ph...

The UK's Advertising Standards Authority has banned the first ads for oral GLP-1 weight loss medicines, targeting waitli...

Two new studies link GLP-1 medications to higher rates of hair loss, scalp inflammation and nail detachment — changes no...

Novo Nordisk will cut Wegovy's US list price by 50% to $675 a month from January 2027, with Ozempic down 35%, as competi...

Tesamorelin's preferential visceral fat reduction makes waist circumference the key tracking metric....

Tesamorelin + MOTS-c + Retatrutide: The Metabolic Stack Guide — a detailed guide covering mechanism, dosing, and researc...

Research supports tesamorelin's potential for reducing liver fat in non-alcoholic fatty liver disease....

A meta-analysis confirms tesamorelin's targeted visceral fat reduction effects across multiple trial populations....

Full TRIUMPH-1 results confirm retatrutide produced 25% average weight loss at 80 weeks in peer-reviewed data. What the ...

Which GLP-1 drugs hold FDA approval for diabetes versus weight loss in 2026? PepsReview breaks down the labels, the off-...

Hundreds of GLP-1 injury lawsuits now sit in New Jersey courts. PepsReview breaks down the claims, the timeline and what...

Lilly's ACHIEVE-4 trial shows oral GLP-1 Foundayo met cardiovascular safety goals while cutting weight and A1C in adults...

CJC-1295 and Ipamorelin Stack: Growth Hormone Optimization Guide — a detailed guide covering mechanism, dosing, and rese...

Tesamorelin's clinical value extends beyond visceral fat reduction to liver health and growth hormone optimization....

TB-500 is the synthetic active fragment of thymosin beta-4 — here's how it works and what the research shows....

CJC-1295 with DAC vs Without DAC: Which Is Right for You? — a detailed guide covering mechanism, dosing, and research ev...

Everything you need to know about BPC-157 in one place — from mechanism of action to dosing protocols to the latest rese...

2026 human trials of TB-500 for cardiac recovery show promising results in post-heart attack tissue repair protocols....

South Africa's largest private health plan reports GLP-1 claims nearly tripled to 61,200 members — while members claim f...

From skin wounds to internal ulcers, BPC-157's wound healing properties are backed by the most robust preclinical eviden...

BPC-157 and TB-500 are the most popular healing peptide combination — here's what you need to know about mixing and usin...

GLP-1 prescribing for US children ages 8-11 rose 310-fold from 2019 to 2026, a Pediatrics study finds — mostly off-label...

BPC-157's effects on tendon repair represent some of the strongest preclinical evidence for the peptide's healing capabi...

BPC-157 promotes tissue healing through angiogenesis, collagen synthesis, and inflammatory modulation — here's how the c...

FDA approved 22 novel drugs in Q3 2026, including peptide therapeutics enlicitide and rusfertide. What the quarter means...

A detailed look at BPC-157's safety evidence across animal studies, human reports, and pharmacovigilance data....

Breaking down the 36-study systematic review of BPC-157 — methodology, outcomes, and what the evidence actually supports...

The FDA's warning on unapproved GLP-1 drugs gains urgency as retatrutide poison-center exposures surge 265% — here is wh...

The FDA closes 2026 with seven pivotal decisions, led by bepirovirsen's October 26 hepatitis B ruling plus calls on obin...

Lilly's EloraTZP — eloralintide plus tirzepatide — delivered up to 23.3% weight loss and deep A1C cuts at 48 weeks, with...

Federal prosecutors unsealed charges against two Dubai men for smuggling counterfeit Ozempic from China — a scheme that ...

Northwestern scientists showed an experimental RNA therapy reprogrammed fat to burn calories, preserving lean mass durin...

A comprehensive review of 36 published studies on BPC-157 reveals consistent healing effects across musculoskeletal tiss...

The regulatory status of BPC-157 shifted significantly in 2026, with implications for compounding access and research....

A regulator-mandated Scandinavian registry study of 97,464 semaglutide users found no increased pancreatic cancer risk, ...

Real-world data on 636,525 adults links semaglutide dose escalation to 6% lower MACE risk vs switching to tirzepatide. W...

BPC-157 demonstrates protective effects against ischemia-reperfusion injury in multiple tissue types, according to emerg...

A 2026 human study on BPC-157 for chronic knee pain shows significant improvements in pain scores and mobility metrics....

GLP-1s are now sold as lifestyle products for 'customers' rather than medicines for patients — reshaping supply, oversig...

The first controlled human trial of BPC-157 is now enrolling participants, marking a pivotal shift from animal data to c...

New 2026 data from human hamstring injury cases treated with BPC-157 shows promising recovery timelines compared to stan...

The unregulated peptide market is projected to reach $50-75 billion by 2028 as FDA rulemaking stalls and clinicians warn...

The TAME metformin longevity trial has FDA-agreed design but zero participants after a decade — a case study in off-pate...

IGF-1 LR3 vs HGH: Dosing Comparison and Muscle Growth Guide — a detailed guide covering mechanism, dosing, and research ...

Copper Peptides for Diabetic Wounds: What the Hydrogel Study Shows — a detailed guide covering mechanism, dosing, and re...

A records study of 300M+ U.S. health charts finds 1.1M adults got GLP-1 prescriptions with no approved medical reason an...

An attorney describes life-changing GLP-1 drug injuries in the growing lawsuit against Novo Nordisk and Eli Lilly — what...

The FDA's removal of GHK-Cu from Category 2 has implications for compounding access and product availability....

5-Amino-1MQ Dosage: Comparing Oral and Subcutaneous Administration — a detailed guide covering mechanism, dosing, and re...

Actimed completes PROACT Phase 2a enrollment, testing whether S-pindolol benzoate preserves muscle during and after sema...

FDA sent August 2026 warning letters to four DTC peptide sellers over unapproved-drug marketing, even as the 503A compou...

A national claims analysis found 16.8% of pediatric GLP-1 users developed nutritional deficiencies within a year, led by...

Hormone replacement therapy dosing compared across routes: estradiol patch doses, tablet doses, and cream dosing — with ...

A guided tour of the full PepsReview calculator suite: dosage protocol calculators, the reconstitution calculator, the u...

The FDA's latest GLP-1 compounder warning letter cites contamination risk from insanitary production conditions. What it...

A new lawsuit alleges manufacturers and PBMs colluded on insulin and GLP-1 pricing. What the case means for drug costs a...

Eli Lilly's once-weekly basal insulin cleared the FDA, escalating its rivalry with Novo Nordisk. What the decision means...

The complete Zepbound (tirzepatide, weight-management brand) dosage schedule: the six KwikPen strengths, four-week titra...

Enclomiphene raises natural testosterone by blocking estrogen feedback at the pituitary — the SERM answer to "TRT or not...

A new Cureus FAERS analysis examines musculoskeletal adverse event signals for semaglutide, liraglutide, and tirzepatide...

Viking's VK2735 maintenance trial kept up to 97% of weight loss after stepping down to monthly or biweekly GLP-1/GIP dos...

The complete Wegovy (semaglutide 2.4 mg) titration schedule: all five pen strengths, the weekly escalation ladder, what ...

The complete Mounjaro and Zepbound (tirzepatide) dosage schedule: six dose strengths, the four-week escalation ladder, K...

Roche's enicepatide cut HbA1c by 2.65% and drove 15.5% weight loss in a Phase 2 diabetes trial, setting up Phase 3 progr...

The FDA's September 2026 warning letter takes aim at Empower Pharmacy's GLP-1 production - the latest in a multi-year pa...

Twenty state attorneys general seek tighter FDA Green List oversight of GLP-1 ingredient imports after a listed Chinese ...

The FDA has hit a Sinopep subsidiary with an import ban suspending its peptide API sales to the US — what researchers ne...

The gut-focused peptides with real research — BPC-157 for mucosal healing, larazotide for tight-junction integrity, KPV ...

Which peptides actually suppress appetite and by what mechanism — GLP-1s by far the leaders, plus amylin analogs (cagril...

Biophytis files an amendment to extend OBA, its Phase 2 trial pairing the muscle-preserving candidate BIO101 with semagl...

New clinical-practice data suggest oral GLP-1 tablets curb snacking less than injections, with modest but real dietary s...

Novo courts restive investors with consumer-health plans and blockbuster pipeline bets as Eli Lilly tightens its grip on...

FDA escalates warnings on compounded GLP-1 drugs while its own adverse-event data reveal gaps — and what both sides mean...

Novo Nordisk's CagriSema posted 12.4% weight loss versus 9.1% for tirzepatide in phase 3, with an FDA weight-management ...

A 63,000-patient records study links higher semaglutide doses to fewer new psychiatric diagnoses, independent of how muc...

GLP-1 development accelerates in 2026 even as NAION vision-loss lawsuits grow. What the pipeline expansion means for res...

Which peptides have real evidence for energy, fatigue, and mitochondrial function — MOTS-c, NAD+, SS-31, BPC-157 for rec...

The peptides with real skin evidence — copper peptides (GHK-Cu), collagen peptides, and topical formulations — including...

NAION vision-loss claims against GLP-1 makers have reached 216 consolidated federal cases in MDL-3166, with Mounjaro use...

Ozempic's higher-dose era: a 2 mg weekly injection plus FDA-cleared oral tablets in 1.5, 4 and 9 mg strengths — and what...

Primo TRT gummies are marketed with testosterone-therapy framing but contain no testosterone. An honest review of the in...

Peptide capsules and pills are everywhere — BPC-157 capsules, collagen peptides, oral GHK-Cu. Which peptides survive the...

FDA warning letters and legal analysis confirm 'Research Use Only' labels don't protect peptide vendors. What it means f...

Novo Nordisk sued Eli Lilly in federal court over allegedly misleading Zepbound and Mounjaro ad campaigns, seeking a per...

A 1.4 million-patient study links GLP-1 drugs to lower ascites rates and reduced all-cause mortality in MASH, with one s...

Eli Lilly filed six lawsuits against retatrutide sellers marketing the unapproved obesity drug to consumers, part of a w...

Health Canada approved Sandoz Semaglutide, the first generic version of Ozempic — a milestone for GLP-1 access and affor...

A new study finds GLP-1 drugs produce weight loss at low starter doses with significantly less nausea, but results unlik...

Newly filed lawsuits blame Mounjaro and Ozempic for sudden vision loss, extending GLP-1 eye-damage litigation to both El...

An FDA advisory panel recommended six peptides for pharmacy compounding in July 2026. The agency has yet to rule, and cl...

The FDA has approved the first oral GLP-1 weight-loss pill. Here is the full 2026 landscape of oral GLP-1 options — what...

Telehealth TRT is now mainstream — and it has a copycat problem: supplement gummies marketed with "TRT" branding that ar...

Alabama's attorney general leads a state coalition framing exploitation of FDA-approved drugs by China's supply chain as...

Peptides discussed for women's health contexts — skin (GHK-Cu, collagen), body composition (GLP-1s), libido (PT-141), re...

Every GLP-1 receptor agonist tracked by researchers in 2026 — semaglutide, tirzepatide, retatrutide, liraglutide, survod...

A 2026 benchmark of research peptide prices across Canadian-facing storefronts: BPC-157, retatrutide, tirzepatide, GHK-C...

Novo Nordisk and Eli Lilly have filed for South Korean approval of their oral GLP-1 obesity pills, setting up a launch r...

Orforglipron is the first FDA-approved oral GLP-1 for weight loss. Its dose-finding history: the Phase 2 1-36 mg range, ...

The FDA approved the first oral GLP-1 weight-loss pill — Eli Lilly's orforglipron (development code Foundayo). What the ...

Novo Nordisk exits its $285 million once-monthly GLP-1 pact with Ascendis Pharma, returning rights as its pipeline reset...

Federal Open Payments data shows Eli Lilly and Novo Nordisk paid over 270,000 US doctors to promote GLP-1 weight-loss dr...

A new study links GLP-1 weight-loss drugs to a rare brain disorder driven by thiamine depletion from rapid weight loss —...

No GLP-1 patch has FDA approval. Every licensed GLP-1 is an injection or tablet, and peptide chemistry blocks skin deliv...

GHK-Cu promotes tissue remodeling through collagen synthesis, anti-inflammatory effects, and stem cell activation....

Phase 2 results for GHK-Cu topical gel show accelerated wound healing in diabetic patients....

Wegovy users with sudden vision loss are being recruited for NAION claims as semaglutide litigation expands - what regul...

Thailand moved weight-loss injection pens to prescription-only from September 15, 2026, ending over-the-counter GLP-1 sa...

GHK-Cu stimulates collagen and elastin production, making it one of the most evidence-backed peptides for skin repair....

GHK-Cu modulates expression of over 4,000 genes, including those involved in tissue repair and anti-aging....

A counterfeit product sold as a peptide contained a large semaglutide dose and hospitalized a New Zealand user, exposing...

Novo Nordisk rebrands as Novo with a new logo and a cultural reset as it battles Eli Lilly for the GLP-1 obesity market....

Dr. Michael Burgess urges FDA to end its GLP-1 Green List after a relabeled Chinese semaglutide case and 21% noncomplian...

GLP-1 vision-loss litigation expands beyond tirzepatide as Saxenda users are recruited for NAION claims over liraglutide...

Complete overview of MOTS-c — the mitochondrial-encoded peptide activating AMPK, improving insulin sensitivity, and link...

GHK-Cu shows potential for supporting cognitive health during aging through multiple protective mechanisms....

Australian authorities renew warnings after a patient suffered a torn oesophagus following use of an unapproved peptide ...

GLP-1 litigation over Eli Lilly's Zepbound is active in federal court in 2026. Who may qualify to file, the injuries all...

Updated September 2026 claims in the Empower Pharmacy lawsuit target compounded GLP-1s, FDA warning letters, and testing...

Morning or evening, fasted or fed, training day or rest — the timing conventions for MOTS-c injections, what circadian A...

Two different anti-aging peptide mechanisms aimed at the same problem — MOTS-c's mitochondrial signaling vs GHK-Cu's tis...

FDA has run a coordinated enforcement sweep against peptide sellers marketing unapproved products, amid a wider Washingt...

A free evidence checker for peptide claims has launched as verification tools multiply across the research peptide marke...

A new market intelligence index catalogs 100+ peptide vendors, 3,200+ listings and 112,000+ public COA records. How rese...

Oral GLP-1 prescriptions keep climbing as the Wegovy pill and Lilly's oral tablet ramp up. What the tablet shift means f...

Aggressive marketing, compounded copies, and purity concerns have put the GLP-1 weight-loss market under fire. Here is w...

Aging widens the gap between training load and recovery capacity. MOTS-c's exercise-mimetic signaling sits at that gap —...

The most medical frontier of MOTS-c research — organ preservation, ischemia-reperfusion protection, and why transplant s...

FDA approves Eli Lilly's oral GLP-1 weight-loss pill, a needle-free option that reshapes obesity care, telehealth supply...

Semaglutide supply has recovered, ending the shortage that fueled compounded copies. The enforcement window is closing o...

Retatrutide still has no FDA approval in 2026. What the Phase 3 TRIUMPH timeline means for researchers and why gray-mark...

Third-party analytical testing for research peptides is scaling up as purity and mislabeling complaints grow. What stron...

New data show GLP-1 prescriptions rising in children under 12 as semaglutide trial results reshape pediatric obesity car...

China has approved semaglutide (Wegovy) as the first GLP-1 treatment for MASH liver disease, opening a new regulatory an...

Lawsuits linking Zepbound and Trulicity to NAION vision loss are mounting against Eli Lilly, raising fresh safety questi...

Moonwalk has raised $70M to move a fat-targeting RNAi obesity candidate into clinical development, adding a new mechanis...

Novo Nordisk's IL-6 inhibitor failed two more cardiovascular outcome trials, a setback for inflammation-driven heart dis...

UK regulators froze over £200,000 in bank accounts and seized thousands of illicit GLP-1 doses in Operation Dunlin — wha...

Compounded semaglutide and tirzepatide have drawn more than 1,700 federal adverse event reports. We break down the FDA d...

South Africa's High Court refused a compounding pharmacy's appeal in the semaglutide fight with Novo Nordisk, keeping th...

Medicine-safety monitors highlight researchers' blunt warning that clinical evidence for most consumer peptides is missi...

Clinicians are raising safety concerns as peptide self-medication goes mainstream. Verification standards protect resear...

The newest MOTS-c research thread — plasma membrane repair, wound-response signaling, and why cell-boundary integrity be...

The strongest human data for MOTS-c is metabolic — what prediabetes research shows, the insulin sensitivity trial result...

The research journey of MOTS-c — 2013 discovery, mechanism characterization, metabolic trial results, and the open quest...

Why MOTS-c and NAD+ are the most-researched pairing in the mitochondrial longevity stack — complementary mechanisms, pro...

How to structure long-term MOTS-c research — cycling conventions, washout rationale, lab-based checkpoints, and designin...

How MOTS-c biases cellular metabolism between repair and conservation — AMPK tone, stress-response gene regulation, and ...

FDA is screening GLP-1 ingredients (semaglutide, tirzepatide) at U.S. borders and warns of vials labeled with pharmacies...

The MOTS-c / MSC research thread — AMPK signaling, stem cell senescence, tissue repair axes, and where evidence ends and...

The MOTS-c / pulmonary inflammation research thread — ARDS models, AMPK anti-inflammatory signaling, COPD/asthma adjacen...

Why atrial fibrillation researchers are watching MOTS-c — mitochondrial dysfunction in AF, AMPK energetics, and what cur...

Daily versus weekly MOTS-c dosing — pharmacokinetic reasoning, protocol conventions, cycling windows, and a practical de...

Why maintenance after GLP-1 weight loss is metabolically vulnerable, and how MOTS-c's AMPK mechanism fits the post-GLP-1...

2026 pilot research on MOTS-c and arterial stiffness — pulse wave velocity findings, mechanism through ETAR, and what it...

Why waist circumference is the single most informative retatrutide progress metric — visceral fat loss, cardiometabolic ...

A realistic walkthrough of the first 14 days on MOTS-c — injection-site response, the subtle metabolic shift, timeline o...

Retatrutide attacks visceral fat preferentially — imaging sub-studies, liver fat reduction, and why fat location predict...

Direct comparison of retatrutide vs tirzepatide — weight loss data, side effect profiles, dosing ladders, cost, and who ...

Retatrutide drives total weight loss; tesamorelin targets visceral fat and supports the GH axis. The logic, risks, and r...

Practical, evidence-based strategies for preserving training energy, strength, and lean mass on retatrutide — from prote...

TRIUMPH-4 delivered 28.7% mean weight loss — 71.2 lbs over 68 weeks at 12 mg — with consistent efficacy across demograph...

Retatrutide's 28.7% average weight loss approaches bariatric surgery territory — honest comparison of efficacy, safety, ...

Retatrutide shows promise for patients with obesity and chronic kidney disease, according to recent meta-analysis data....

The TRIUMPH-1 trial establishes retatrutide's efficacy for chronic weight management in adults with obesity....

Retatrutide may preserve muscle better than other GLP-1s due to its glucagon receptor activity — here's the science....

A practical troubleshooting guide for when retatrutide weight loss stalls or doesn't seem to work....

Some retatrutide users report heat sensitivity and temperature regulation issues — here's what the data shows....

The July 2026 Phase 3 data readout for retatrutide provides the most comprehensive efficacy picture yet....

Tracking the retatrutide FDA approval process — key milestones, expected dates, and what could delay approval....

A practical first-dose guide for retatrutide — titration schedule, side effect management, and timeline expectations....

A practical guide to tracking body composition on retatrutide therapy — what metrics matter and how often to measure....

As retatrutide enters compounding pharmacies, quality control standards become critical for user safety....

Retatrutide's 2026 trial data shows benefits beyond weight loss, including back pain reduction and liver health improvem...

The TRIUMPH-4 trial confirms retatrutide achieves up to 31% weight loss, setting a new benchmark in GLP-1 therapy....

Discover the benefits of TB 500 and BPC 157, peptide compounds discussed for recovery and repair. Learn about TB 500 dos...

Discover how peptide purity testing cost varies based on method, scope, and location. Learn to compare options for relia...

Discover what realistic peptides before and after results entail, from skin texture improvement to hydration and radianc...

Discover if semaglutide is the same as Ozempic or Wegovy. Learn about their uses, benefits, and differences for type 2 d...

Explore the comprehensive guide on liraglutide weight loss price, including cost factors, insurance impact, and saving s...

Discover why tirzepatide may be better than semaglutide for some in weight loss and diabetes control. Explore tirzepatid...

Explore the benefits and considerations of taking peptides, a growing health trend offering potential advantages in meta...

Explore the essential role of testing peptides in research, ensuring quality through identity and purity assessments. Le...

Discover how peptides for healing enhance tissue repair, recovery, and wellness. Learn about peptide therapy, tendon rec...

Tesamorelin and Ipamorelin: The Growth Hormone Stack GLP-1 Users Love. What tesamorelin does (GHRH analog, FDA-approved ...

Cagrilintide: The Amylin Analog Being Stacked with GLP-1s. What cagrilintide is (amylin analog). How it complements GLP-...

GHK-Cu: The Copper Peptide for Skin, Hair, and Healing. What GHK-Cu does at cellular level. Skin collagen and elasticity...

Switching from Semaglutide to Retatrutide: Complete Guide. Why users switch (better efficacy, fewer side effects). Dosin...

GLP-1 Cost Comparison: How to Get the Best Price Per Milligram. Price per mg across vendors (forum data: <$1/mg is good,...

GLP-1 Side Effects: What Real Users Actually Experience. Nausea, diarrhea, constipation timeline. When side effects peak...

Peptide Stacking 101: What GLP-1 Users Are Combining. Most popular stacks from forum data. Tirz + Semaglutide (cagrisema...

When GLP-1 Weight Loss Stalls: Breaking Through Plateaus. What counts as a stall (forum consensus: 3+ weeks no loss). Wh...

BPC-157 and TB-500: The Ultimate Tissue Repair Stack. What BPC-157 does. What TB-500 does. Why stacking them works syner...

Tirzepatide vs Semaglutide: Which GLP-1 Actually Works Better?. Dual GIP/GLP-1 vs single GLP-1. Head-to-head weight loss...

How to Read a Peptide COA: Complete Guide for GLP-1 Buyers. What a COA looks like. HPLC vs LC-MS explained. How to inter...

Retatrutide: The Triple Agonist Everyone Is Talking About. What makes retatrutide different (triple receptor). Clinical ...